Document is current
Any future updates will be listed below
-
Authors
Ottina, Eleonora https://orcid.org/0000-0002-9630-496X
Panova, Veera https://orcid.org/0000-0001-8433-6430
Doglio, Laura
Kazachenka, Anastasiya
Cornish, Georgina
Kirkpatrick, Joanna
Attig, Jan https://orcid.org/0000-0002-2159-2880
Young, George R. https://orcid.org/0000-0002-1203-588X
Litchfield, Kevin https://orcid.org/0000-0002-3725-0914
Lesluyes, Tom https://orcid.org/0000-0003-2251-5884
Van Loo, Peter https://orcid.org/0000-0003-0292-1949
Swanton, Charles https://orcid.org/0000-0002-4299-3018
MacRae, James https://orcid.org/0000-0002-1464-8583
Tüting, Thomas https://orcid.org/0000-0001-7146-0934
Kassiotis, George https://orcid.org/0000-0002-8457-2633
- License Information
-
More Information
Article History
Received: 11 January 2021
Revised: 14 May 2021
Accepted: 1 June 2021
First Online: 18 June 2021
Change Date: 29 July 2021
Change Type: Update
Change Details: The name of Peter Van Loo was given incorrect in HTML version of the article. Correct is: Given name: Peter Family name: Van Loo
Competing interests
: GK is a scientific co-founder of EnaraBio and a member of its scientific advisory board. GK and GRY are consulting for EnaraBio. CS acknowledges grant support from Pfizer, AstraZeneca, Bristol Myers Squibb, Roche-Ventana, Boehringer-Ingelheim, Archer Dx Inc (collaboration in minimal residual disease sequencing technologies) and Ono Pharmaceutical, is an AstraZeneca Advisory Board member and Chief Investigator for the MeRmaiD1 clinical trial, has consulted for Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol Myers Squibb, Celgene, AstraZeneca, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi, Bicycle Therapeutics, and the Sarah Cannon Research Institute, has stock options in Apogen Biotechnologies, Epic Bioscience, GRAIL, and has stock options and is co-founder of Achilles Therapeutics.
